Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
SNGXNEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
SNGX50 of 80 patients enrolled in FLASH2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
SNGX(NASDAQ:SNGX) Two Year Stability demonstrated in both bivalent and trivalent configurations at temperatures of 40°C / 104°F PRINCETON, N.J., Sept. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and...
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SNGX(NASDAQ:SNGX) PRINCETON, N.J., Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher...
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
SNGXProvides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare...
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
SNGXPRINCETON, N.J., Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent...
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
SNGXSangamo Therapeutics reports recent business highlights and second quarter 2025 financial results
Soligenix Q1 EPS $(1.06) Misses $(0.67) Estimate
SNGXWatching Soligenix; Zacks Small-Cap Research Gives Stock $35 Price Valuation
SNGXSoligenix Announces Interim Results From Ongoing Open-Label Investigator-Initiated Study Of HyBryte; Says Following 18 Weeks Of Treatment, 75% Of Patients Achieved 'Treatment Success'
SNGXWatching Soligenix; Zacks Small-Cap Research Gives Stock $35 Price Valuation
SNGXSoligenix Reports Publication Describing Preclinical Efficacy Of CiVax, A Thermostabilized Subunit Vaccine Against SARS-CoV-2
SNGXSoligenix Reported Revenues Of $0.1M For Year Ended December 31, 2024, Compared To $0.8M YoY; Company's Cash Position Was $7.8M
SNGXSoligenix To Present At USCLC Workshop 'Cutaneous Lymphomas in Special Populations' March 6 And AAD Annual Meeting, March 7-11
SNGXWatching Soligenix; Zacks Small-Cap Research Gives Stock $35 Price Valuation
SNGXSoligenix shares are trading higher after the company announced interim data from its investigator-initiated study of HyBryte for early-stage cutaneous T-cell lymphoma, which showed over 70% of patients who completed at least 18 weeks of therapy achieved
SNGXEXCLUSIVE: Soligenix Tells Benzinga 'Patients have responded positively to HyBryte therapy, with over 70% (5 of the 6 subjects who have completed at least 18 weeks of therapy) already achieving Treatment Success'
SNGXEXCLUSIVE: Soligenix Tells Benzinga 'Study Supported by $2.6 Million FDA Orphan Products Development Grant'
SNGXEXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
SNGXSoligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing.
EXCLUSIVE: Soligenix Tells Benzinga HyBryte Expanded Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma
SNGXSoligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
SNGXSoligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
SNGXSoligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
Soligenix Initiates A Phase 2 Clinical Trial Of SGX945 For The Treatment Of Behçet's Disease; Says Study DUS-AUBD-01 Opens Patient Enrollment
SNGXSoligenix Receives Notice Of Allowance For U.S. Patent Titled 'Thermostable Vaccine Compositions and Methods of Preparing same'
SNGXSoligenix Receives Notice Of Allowance For US Patent Application Titled Thermostable Vaccine Compositions And Methods Of Preparing Same
SNGXSoligenix Regains Compliance With Nasdaq Stock Market's Requirement That Co Have Shareholders' Equity Of At Least $2.5M
SNGXSoligenix's Clinical Results From HyBryte Compatibility Study For Cutaneous T-Cell Lymphoma Published In JEADV Clinical Practice
SNGXSoligenix Earnings Perspective: Return On Capital Employed
SNGXAccording to Benzinga Pro data, during Q2, Soligenix (NASDAQ:SNGX) posted sales of $400 thousand. Earnings were up 45.12%, but Soligenix still reported an overall loss of $2.39 million.
